Forde et al.(1) reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USAUniv Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
机构:
Univ Calif Irvine, Med Ctr, Dept Med, Orange, CA USAUniv Calif Irvine, Med Ctr, Dept Med, Orange, CA USA
Grant, Christopher
Nagasaka, Misako
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Irvine, Med Ctr, Dept Med, Orange, CA USA
Univ Calif Irvine, Med Ctr, Dept Med, Div Hematol & Oncol, Orange, CA USAUniv Calif Irvine, Med Ctr, Dept Med, Orange, CA USA